Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma: Milan Monday, June 16, 2025, 14:00 Hrs [IST] Johnson & Johnson an ...

We hope to add results when they are available. This trial is looking at whether atezolizumab can improve treatment for a people with a type of non-Hodgkin lymphoma called diffuse B cell lymphoma ...

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, ...